Welcome to the Heplisav-B Resource Portal

This portal provides access to important information and tools to help facilitate hepatitis B vaccination rates in health systems and drive effective implementation of the Centers for Disease Control and Prevention (CDC) adult hepatitis B vaccination policy.1,2

box of HEPLISAV-B (five doses) with two doses on the table in front of it

Hepatitis B Remains a Clinical and Public Health Burden in the US

In 2019, ~50% of new cases were among adults aged 30-49 years1

In many states, the rate of new cases in adults has increased in the last decade1,3

Due to the lack of an effective adult vaccination strategy, 4 out of 5 adults born before 1991 do not have vaccine-induced immunity3

Adult Hepatitis B Vaccination Guidelines in the US

The CDC Advisory Committee on Immunization Practices (ACIP) issues updated hepatitis B vaccination recommendations for adults.2 The Morbidity and Mortality Weekly Report (MMWR) published the recommendations as official guidelines in April 2022.1

New guidelines simplify hepatitis B vaccine recommendations in adults1,2

All adults aged 19-59 years

checked circle

should receive Hepatitis B vaccination

Adults aged 60 years and older with risk factors*

checked circle

should receive Hepatitis B vaccination

Adults aged 60 years and older without known risk factors

checked circle

may receive Hepatitis B vaccination

*Please refer to the hepatitis B vaccination guidelines noted in the MMWR publication for the specific risk factors for hepatitis B.1

EHR, electronic health record. 


  1. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. 
  2. Murthy N, Wodi AP, Bernstein H, McNally V, Cineas S, Ault K. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233. 
  3. He W-Q, Guo GN, LiC. The impact of hepatitis B vaccination in the United States, 1999-2018. Hepatology. 2022;75(6):1566-1578. 

Important Safety Information


HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 


Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. 

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. 

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. 

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. 

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%). 

Please see full Prescribing Information.